November 26, 2019

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Mothers Code: 4593)
Contact: Richard Kincaid, Executive Officer CFO
(TEL: 03-5777-8308)

Stem Cell Product HLCM051 for ARDS Orphan Regenerative Medicine Official Designation by the Ministry of Health, Labour and Welfare

HEALIOS K.K. ("Healios") is currently conducting clinical trials using the stem cell product HLCM051 for ischemic stroke and acute respiratory distress syndrome (ARDS) patients in Japan.

As announced in the press release on November 14, 2019, "A Stem Cell Product HLCM051 for ARDS Orphan Regenerative Medicine Designation," today Healios announces that the Ministry of Health, Labour and Welfare officially designated HLCM051 as an orphan regenerative medicine for ARDS.

Healios will promptly announce if any matter occurs that must be disclosed.